BB Biotech (Germany) Performance
| BBZA Stock | EUR 39.20 0.70 1.82% |
The firm owns a Beta (Systematic Risk) of 1.21, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, BB Biotech will likely underperform. At this point, BB Biotech AG has a negative expected return of -0.087%. Please make sure to confirm BB Biotech's market risk adjusted performance, coefficient of variation, jensen alpha, as well as the relationship between the mean deviation and standard deviation , to decide if BB Biotech AG performance from the past will be repeated sooner or later.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days BB Biotech AG has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable basic indicators, BB Biotech is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
| Begin Period Cash Flow | 2.8 M | |
| Free Cash Flow | 231.1 M |
BBZA |
BB Biotech Relative Risk vs. Return Landscape
If you would invest 4,195 in BB Biotech AG on August 25, 2024 and sell it today you would lose (275.00) from holding BB Biotech AG or give up 6.56% of portfolio value over 90 days. BB Biotech AG is producing return of less than zero assuming 1.7856% volatility of returns over the 90 days investment horizon. Simply put, 15% of all stocks have less volatile historical return distribution than BB Biotech, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
BB Biotech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for BB Biotech's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as BB Biotech AG, and traders can use it to determine the average amount a BB Biotech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0487
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | BBZA |
Estimated Market Risk
| 1.79 actual daily | 15 85% of assets are more volatile |
Expected Return
| -0.09 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.05 actual daily | 0 Most of other assets perform better |
Based on monthly moving average BB Biotech is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of BB Biotech by adding BB Biotech to a well-diversified portfolio.
BB Biotech Fundamentals Growth
BBZA Stock prices reflect investors' perceptions of the future prospects and financial health of BB Biotech, and BB Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on BBZA Stock performance.
| Return On Equity | -0.12 | |||
| Return On Asset | -0.008 | |||
| Current Valuation | 226.69 M | |||
| Shares Outstanding | 54.85 M | |||
| Price To Earning | 4.19 X | |||
| Price To Book | 1.27 X | |||
| Price To Sales | 800,360 X | |||
| Revenue | (351.23 M) | |||
| Book Value Per Share | 48.98 X | |||
| Cash Flow From Operations | (94.79 M) | |||
| Earnings Per Share | (6.58) X | |||
| Total Asset | 3.05 B | |||
About BB Biotech Performance
By analyzing BB Biotech's fundamental ratios, stakeholders can gain valuable insights into BB Biotech's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if BB Biotech has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if BB Biotech has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Things to note about BB Biotech AG performance evaluation
Checking the ongoing alerts about BB Biotech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for BB Biotech AG help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| BB Biotech AG generated a negative expected return over the last 90 days | |
| BB Biotech AG has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (357.81 M) with profit before overhead, payroll, taxes, and interest of 4 K. | |
| BB Biotech generates negative cash flow from operations |
- Analyzing BB Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether BB Biotech's stock is overvalued or undervalued compared to its peers.
- Examining BB Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating BB Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of BB Biotech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of BB Biotech's stock. These opinions can provide insight into BB Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for BBZA Stock analysis
When running BB Biotech's price analysis, check to measure BB Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BB Biotech is operating at the current time. Most of BB Biotech's value examination focuses on studying past and present price action to predict the probability of BB Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BB Biotech's price. Additionally, you may evaluate how the addition of BB Biotech to your portfolios can decrease your overall portfolio volatility.
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |